News | May 25, 2010

Trial Examines Coronary Stent Delivered by Drug-Eluting Balloon

May 25, 2010 – The first patient has been implanted with a bare metal coronary stent mounted on a drug-eluting balloon in the European Pioneer trial, which began this week.

During stent placement, a predetermined load of the antiproliferative drug paclitaxel is delivered to the vessel wall to help prevent vessel scaring tissue growth inside the stent. The Pioneer drug-eluting balloon is designed to deliver a cobalt chrome alloy bare metal stent.

The team of investigator Dr. Jacques Koolen enrolled the first patient in the Catharina Hospital Eindhoven. This will soon be followed by enrollment in five additional centers in the Netherlands under guidance of the Principal Investigator Peter Smits of Maasstad Hospital Rotterdam.

The drug-eluting balloon product in the Pioneer trial delivers drugs at the stent placement only, instead of continuous drug delivery by drug-eluting stents. This reduces the period that medication is needed, which means total procedure costs may be reduced significantly. The new procedure is supposed to improve a patient's comfort, as the period for which he has to take daily antiplatelet medication is reduced from up to two years to one month.

Blue Medical has developed two drug-eluting balloons, the Pioneer and the Protégé angioplasty balloon.

For more information: www.bluemedical.com

Related Content

PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Overlay Init